


Financial Information FY 2024


(1.10.2023-30.9.2024)

Group


Revenue-Bridge (EURm)



Revenues by region (EURm)



Revenues by segment (EURm)



Results (EURm)	FY24	FY23
Revenues	957	899
EBITDA	258	239
EBITDA margin	26.9%	26.6%
EBITDA margin (at constant currencies)	27.8%	n.a.
EBIT	193	192
EBIT margin	20.1%	21.4%
Financial result	-9	-7
Income tax expense	-34	-34
Profit for the period	150	152
EPS (in EUR)	0.99	1.01
DPS (in EUR)	0.16*	0.15
ROCE	20%	23%


Financial position (EURm)	FY24	FY23
Cash flow from operating activities (A)	225	182
Cash flow from investing activities (B)	-146	-171
Free cash flow (A+B)	79	10

Net assets (EURm)	30.9.2024	30.9.2023
Working Capital	175	186
Working Capital ratio to revenues	18.3%	20.7%
Equity ratio	54.9%	56.2%
Capital employed	980	912
Net debt	119	148

Employees	30.9.2024	30.9.2023
Headcount	4,690	4,646

Drug Containment Solutions (DCS)**


Revenue-Bridge (EURm)



Results (EURm)	FY24	FY23
EBITDA	101	109
EBITDA margin	19.5%	19.6%
EBIT	66	87
EBIT margin	12.8%	15.5%

Drug Delivery System (DDS)**

Revenue-Bridge (EURm)



Results (EURm)	FY24	FY23
EBITDA	166	129
EBITDA margin	37.9%	37.5%
EBIT	137	106
EBIT margin	31.2%	30.9%

*Dividend proposal
**without reconciliation Consolidation